Negative regulation of cytokine signaling influences inflammation

Current Opinion in Immunology

Volumn 15, Issue 6, 2003, Pages 704-708

  Yoshimura, Akihiko ^a   Mori, Hiroyuki ^a   Ohishi, Masanobu ^a   Aki, Daisuke ^a   Hanada, Toshikatsu ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN GP 130; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; SMAD PROTEIN; STAT PROTEIN; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR;

ANTIGEN PRESENTING CELL; BINDING COMPETITION; BINDING SITE; CYTOKINE RELEASE; EMBRYO DEVELOPMENT; ENZYME ACTIVATION; ENZYME INHIBITION; GENE INDUCTION; IMMUNOREGULATION; INFLAMMATION; KNOCKOUT MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; WILD TYPE;

EID: 0242407711     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2003.09.004     Document Type: Review

References (32)

1. Yoshimura A., Ichihara M., Kinjyo I., Moriyama M., Copeland N.G., Gilbert D.J., Jenkins N.A., Hara T., Miyajima A. A novel cytokine-inducible gene CIS encodes an SH2 containing protein that binds to tyrosine- phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14:1995;2816-2826.
2. Yasukawa H., Sasaki A., Yoshimura A. Negative regulation of cytokine signaling pathways. Annu. Rev. Immunol. 18:2000;143-164.
3. Matsumoto A., Seki Y., Kubo M., Ohtsuka S., Suzuki A., Hayashi I., Tsuji K., Nakahata T., Okabe M., Yamada S., Yoshimura A. Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol. Cell. Biol. 19:1999;6396-6407.
4. Endo T.A., Masuhara M., Yokouchi M., Suzuki R., Sakamoto H., Mitsui K., Matsumoto A., Tanimura S., Ohtsubo M., Misawa H., et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature. 387:1997;921-924.
5. Naka T., Narazaki M., Hirata M., Matsumoto T., Minamoto S., Aono A., Nishimoto N., Kajita T., Taga T., Yoshizaki K., et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 387:1997;924-929.
6. Starr R., Willson T.A., Viney E.M., Murray L.J., Rayner J.R., Jenkins B.J., Gonda T.J., Alexander W.S., Metcalf D., Nicola N.A., Hilton D.J. A family of cytokine-inducible inhibitors of signalling. Nature. 387:1997;917-921.
7. Giordanetto F., Kroemer R.T. A three-dimensional model of Suppressor Of Cytokine Signalling 1 (SOCS-1). Protein Eng. 16:2003;115-124 This is an interesting paper that predicts the three-dimensional structure of a JAK2-SOCS1-elongin complex.
8. Sasaki A., Yasukawa H., Suzuki A., Kamizono S., Syoda T., Kinjyo I., Sasaki M., Johnston J.A., Yoshimura A. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells. 4:1999;339-351.
9. Lehmann U., Schmitz J., Weissenbach M., Sobota R.M., Hortner M., Friederichs K., Behrmann I., Tsiaris W., Sasaki A., Schneider-Mergener J., et al. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J. Biol. Chem. 278:2003;661-671.
10. Bjorbak C., Lavery H.J., Bates S.H., Olson R.K., Davis S.M., Flier J.S., Myers M.G. Jr. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J. Biol. Chem. 275:2000;40649-40657.
11. Hortner M., Nielsch U., Mayr L.M., Heinrich P.C., Haan S. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur. J. Biochem. 269:2002;2516-2526.
12. Alexander W.S., Starr R., Fenner J.E., Scott C.L., Handman E., Sprigg N.S., Corbin J.E., Cornish A.L., Darwiche R., Owczarek C.M., et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 98:1999;597-608.
13. Marine J.C., Topham D.J., McKay C., Wang D., Parganas E., Stravopodis D., Yoshimura A., Ihle J.N. SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell. 98:1999;609-616.
14. Metcalf D., Mifsud S., Di Rago L., Nicola N.A., Hilton D.J., Alexander W.S. Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc. Natl. Acad. Sci. USA. 99:2002;943-948 This paper indicates that IFN-γ/SOCS1 double KO mice still suffer from inflammatory diseases. Therefore, this paper suggests that SOCS1 is a negative regulator of inflammatory cytokines in addition to IFN-γ.
15. Egan P.J., Lawlor K.E., Alexander W.S., Wicks I.P. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J. Clin. Invest. 111:2003;915-924 This paper suggests that SOCS1 suppresses antigen-induced autoimmune arthritis.
16. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., Harris C.C., Herman J.G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28:2001;29-35.
17. Hong F., Jaruga B., Kim W.H., Radaeva S., El-Assal O.N., Tian Z., Nguyen V.A., Gao B. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J. Clin. Invest. 110:2002;1503-1513 This paper suggests that STAT1 promoters liver injury, whereas STAT3 protects it.
18. Naka T., Tsutsui H., Fujimoto M., Kawazoe Y., Kohzaki H., Morita Y., Nakagawa R., Narazaki M., Adachi K., Yoshimoto T., et al. SOCS-1/ SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity. 14:2001;535-545.
19. -/- mice.
20. Kinjyo I., Hanada T., Inagaki-Ohara K., Mori H., Aki D., Ohishi M., Yoshida H., Kubo M., Yoshimura A. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 17:2002;583-591 SOCS1 is shown to be required for suppression of LPS signaling in macrophages.
21. Nakagawa R., Naka T., Tsutsui H., Fujimoto M., Kimura A., Abe T., Seki E., Sato S., Takeuchi O., Takeda K., et al. SOCS-1 participates in negative regulation of LPS responses. Immunity. 17:2002;677-687 SOCS1 is shown to be required for suppression of LPS signaling in macrophages.
22. Dalpke A.H., Opper S., Zimmermann S., Heeg K. Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J. Immunol. 166:2001;7082-7089.
23. Roberts A.W., Robb L., Rakar S., Hartley L., Cluse L., Nicola N.A., Metcalf D., Hilton D.J., Alexander W.S. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl. Acad. Sci. USA. 98:2001;9324-9329.
24. Takahashi Y., Carpino N., Cross J.C., Torres M., Parganas E., Ihle J.N. SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J. 22:2003;372-384.
25. Suzuki A., Hanada T., Mitsuyama K., Yoshida T., Kamizono S., Hoshino T., Kubo M., Yamashita A., Okabe M., Takeda K., et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestional inflammation. J. Exp. Med. 193:2001;471-481.
26. Shouda T., Yoshida T., Hanada T., Wakioka T., Oishi M., Miyoshi K., Komiya S., Kosai K., Hanakawa Y., Hashimoto K., et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J. Clin. Invest. 108:2001;1781-1788.
27. Atsumi T., Ishihara K., Kamimura D., Ikushima H., Ohtani T., Hirota S., Kobayashi H., Park S.J., Saeki Y., Kitamura Y., Hirano T. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J. Exp. Med. 196:2002;979-990.
28. Lang R., Pauleau A.L., Parganas E., Takahashi Y., Mages J., Ihle J.N., Rutschman R., Murray P.J. SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4:2003;546-550 This paper also showed that, without SOCS3, IL-6 can now activate STAT1 in addition to STAT3.
29. Yasukawa H., Ohishi M., Mori H., Murakami M., Chinen T., Aki D., Hanada T., Takeda K., Akira S., Hoshijima M., et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4:2003;551-556 This paper demonstrates that SOCS3 is necessary to inhibit IL-6 signaling in macrophages. Without SOCS3, macrophages now can be suppressed not only by IL-10 but also by IL-6.
30. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., Robb L., Greenhalgh C.J., Forster I., Clausen B.E., et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4:2003;540-545 SOCS3 is shown to be an important negative regulator in macrophages.
31. Ernst M., Inglese M., Waring P., Campbell I.K., Bao S., Clay F.J., Alexander W.S., Wicks I.P., Tarlinton D.M., Novak U., et al. Defective gp130-mediated signal transducer and activator of transcription (STAT) signaling results in degenerative joint disease, gastrointestinal ulceration, and failure of uterine implantation. J. Exp. Med. 194:2001;189-203.
32. Tebbutt N.C., Giraud A.S., Inglese M., Jenkins B., Waring P., Clay F.J., Malki S., Alderman B.M., Grail D., Hollande F., et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 8:2002;1089-1097 This paper shows that a gp130 mutant lacking SHP-2 and SOCS3 binding sites induces gastrointestinal inflammatory diseases.